spacer
home > white papers > Keeping Abreast of the Competitive Environment in Clinical Development - Thomson Reuters
WHITE PAPERS
logo_Thomson_Re.JPG

Thomson Reuters

phone +1 800.336.4474 (North America) +44 20.7433.4000 (Europe, Middle East and Africa)
web http://thomsonreuters.com/
email 1500 Spring Garden Street, Fourth Floor, Philadelphia, PA 19130 USA

Keeping Abreast of the Competitive Environment in Clinical Development


Keeping Abreast of the Competitive Environment in Clinical Development
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Strategic Alliance to support efficient, ethical practices in biopharma industry

Hayward, CA and Stockholm, Sweden (07-12-2017) – Two leading drug development and regulatory consultancies announced today that they have formed a new strategic collaboration to help life science companies navigate an increasingly complex global environment. Ethiprax Associates LLC, a leading Compliance and Ethics solutions consultancy based in the US, and NDA Group, a world-leading integrated regulatory/drug development consultancy, are now collaborating to provide the life science industry with truly integrated, trans-Atlantic Compliance-and Risk Management strategies.
More info >>


White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>


Industry Events

Drug Delivery Partnerships 2018

22-24 January 2018, PGA National Resort & Spa, Palm Beach Gardens, Florida

For 22 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement